Current Liabilities
Accrued Expenses
Biogen Accrued Expenses decreased by 9.1% to $2.55B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1224.4%, from $192.3M to $2.55B. Over 5 years (FY 2020 to FY 2025), Accrued Expenses shows a downward trend with a -2.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
First reportedQ4 2014
Last reportedQ1 2026Apr 29, 2026
Metric ID:
accrued_expensesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $242.5M | $299.2M | $2.54B | $206.6M | $281.5M | $313.5M | $2.52B | $187.2M | $253.3M | $276.7M | $2.62B | $164.1M | $228.3M | $288.7M | $2.81B | $192.3M | $260.9M | $310.7M | $2.8B | $2.55B |
| QoQ Change | — | +23.4% | +747.3% | -91.9% | +36.3% | +11.4% | +704.3% | -92.6% | +35.3% | +9.2% | +848.2% | -93.7% | +39.1% | +26.5% | +872.5% | -93.2% | +35.7% | +19.1% | +802.0% | -9.1% |
| YoY Change | — | — | — | — | +16.1% | +4.8% | -0.5% | -9.4% | -10.0% | -11.7% | +4.1% | -12.3% | -9.9% | +4.3% | +7.0% | +17.2% | +14.3% | +7.6% | -0.2% | >999% |
Range$164.1M – $2.81B
CAGR+64.1%
Avg YoY Growth+77.9%
Median YoY Growth+4.2%
Accrued Expenses at Other Companies
Frequently Asked Questions
- What is Biogen's accrued expenses?
- Biogen (BIIB) reported accrued expenses of $2.55B in Q1 2026.
- How has Biogen's accrued expenses changed year-over-year?
- Biogen's accrued expenses increased by 1224.4% year-over-year, from $192.3M to $2.55B.
- What is the long-term trend for Biogen's accrued expenses?
- Over 5 years (2020 to 2025), Biogen's accrued expenses has grown at a -2.3% compound annual growth rate (CAGR), from $3.15B to $2.8B.